InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

- Current share price for MSB : $2.160

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,811 Notification of cessation of securities - MSB 15 Apr 2024 5:02PM $0.830 $2.160 risen by 160.24%
$2,811 Change in substantial holding 9 Apr 2024 9:23AM $0.925 $2.160 risen by 133.51%
$2,811 Change in substantial holding 2 Apr 2024 9:53AM $0.555 $2.160 risen by 289.19%
$2,811 FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA 26 Mar 2024 1:05PM $0.330 $2.160 risen by 554.55%
$2,811 Pause in Trading 26 Mar 2024 9:52AM $0.330 $2.160 risen by 554.55%
$2,811 Cleansing Notice 26 Mar 2024 9:48AM $0.330 $2.160 risen by 554.55%
$2,811 Application for quotation of securities - MSB 22 Mar 2024 4:32PM $0.335 $2.160 risen by 544.78%
$2,811 Change in substantial holding 20 Mar 2024 9:46AM $0.335 $2.160 risen by 544.78%
$2,811 Proposed issue of securities - MSB 20 Mar 2024 9:37AM $0.335 $2.160 risen by 544.78%
$2,811 Cleansing Notice 19 Mar 2024 8:45AM $0.340 $2.160 risen by 535.29%
$2,811 Appendix 2A 18 Mar 2024 12:09PM $0.340 $2.160 risen by 535.29%
$2,811 Proposed issue of securities - MSB 14 Mar 2024 4:55PM $0.370 $2.160 risen by 483.78%
$2,811 Mesoblast Completes Placement and Entitlement Offer 14 Mar 2024 9:54AM $0.375 $2.160 risen by 476%
$2,811 FDA Supports Accelerated Approval Pathway for Heart Failure 11 Mar 2024 9:57AM $0.315 $2.160 risen by 585.71%
$2,811 MSB Q2 Financial Results and Operational Highlights 29 Feb 2024 8:54AM $0.300 $2.160 risen by 620%
$2,811 Half Year Financial Results Presentation 29 Feb 2024 8:49AM $0.300 $2.160 risen by 620%
$2,811 Half Year Report and Accounts (including Appendix 4D) 29 Feb 2024 8:46AM $0.300 $2.160 risen by 620%
$2,811 Mesoblast 2024 Half Year Financial Results Webcast 26 Feb 2024 5:00PM $0.295 $2.160 risen by 632.20%
$2,811 FDA Grants Orphan Drug Designation for Revascor 15 Feb 2024 10:46AM $0.280 $2.160 risen by 671.43%
$2,811 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2024 12:39PM $0.270 $2.160 risen by 700%
$2,811 FDA Grants Rare Pediatric Disease Designation for Revascor 19 Jan 2024 9:56AM $0.265 $2.160 risen by 715.09%
$2,811 App 3Ys S Itescu,E Rose,J Swedish,B Burns,J Bell,P Facchina 15 Jan 2024 5:33PM $0.280 $2.160 risen by 671.43%
$2,811 Notification regarding unquoted securities - MSB 15 Jan 2024 5:19PM $0.280 $2.160 risen by 671.43%
$2,811 Notification of cessation of securities - MSB 15 Jan 2024 5:11PM $0.280 $2.160 risen by 671.43%
$2,811 Appendix 3Y for Joseph Swedish 3 Jan 2024 5:23PM $0.290 $2.160 risen by 644.83%

301 - 325 of 1203 results

Page 13 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.